Potrójnie ujemne raki piersi — leczenie i nowe strategie terapeutyczne

Ditkowska J, Wojciechowska U, Olasek P. Onkologia.org.pl. https://onkologia.org.pl/sites/default/files/publications/2022-05/Nowotwory_2019.pdf. Accessed February 7, 2023.

Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Advances in Anatomic Pathology. 2019;27(1):27-35. doi:10.1097/pap.0000000000000232

Zubair M, Wang S, Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol. 2021;11. doi:10.3389/fphar.2020.632079

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304

Prat A, Adamo B, Cheang MCU, Anders CK, Carey LA, Perou CM. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer. The Oncologist. 2013;18(2):123-133. doi:10.1634/theoncologist.2012-0397

Atchley DP, Albarracin CT, Lopez A, et al. Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer. JCO. 2008;26(26):4282-4288. doi:10.1200/jco.2008.16.6231

Meyer P, Landgraf K, Högel B, Eiermann W, Ataseven B. BRCA2 Mutations and Triple-Negative Breast Cancer. Toland AE, ed. PLoS ONE. 2012;7(5):e38361. doi:10.1371/journal.pone.0038361

Chen H, Wu J, Zhang Z, et al. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol. 2018;9. doi:10.3389/fphar.2018.00909

Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions of BRCA1 and BRCA2 mutations to “triple-negative” breast cancer in Ashkenazi Women. Breast Cancer Res Treat. 2011;129(1):185-190. doi:10.1007/s10549-011-1433-2

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109(9):1721-1728. doi:10.1002/cncr.22618

Qiu J, Xue X, Hu C, et al. Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer. J Cancer. 2016;7(2):167-173. doi:10.7150/jca.10944

Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-2767. doi:10.1172/jci45014

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology. 2011;22(8):1736-1747. doi:10.1093/annonc/mdr304

Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. Breast Cancer. 2011;18(3):165-173. doi:10.1007/s12282-011-0254-9

Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12(2):106-116. doi:10.7497/j.issn.2095-3941.2015.0030

Berrada N, Delaloge S, André F. Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Annals of Oncology. 2010;21:vii30-vii35. doi:10.1093/annonc/mdq279

Gośliński J. Operacja Oszczędzająca Pierś I Mastektomia W Chirurgicznym leczeniu Raka Sutka. Zwrotnikraka.pl. https://www.zwrotnikraka.pl/operacja-oszczedzajaca-piers-mastektomia-rak-sutka/. Published April 29, 2021. Accessed February 9, 2023.

Skotnicki P. Kwadrantektomia – Operacja oszczędzająca W leczeniu Raka Piersi. Szpital na Klinach. https://www.szpitalnaklinach.pl/blog/kwadrantektomia-operacja-oszczedzajaca-w-leczeniu-raka-piersi/. Accessed February 9, 2023.

Adkins FC, Gonzalez-Angulo AM, Lei X, et al. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Ann Surg Oncol. 2011;18(11):3164-3173. doi:10.1245/s10434-011-1920-z

Fancellu A, Houssami N, Sanna V, Porcu A, Ninniri C, Marinovich ML. Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis. British Journal of Surgery. 2021;108(7):760-768. doi:10.1093/bjs/znab145

Barbieri V, Sanpaolo P, Genovesi D. Prognostic Impact of Triple Negative Phenotype in Conservatively Treated Breast Cancer. The Breast Journal. 2011;17(4):377-382. doi:10.1111/j.1524-4741.2011.01100.x

Abdulkarim BS, Cuartero J, Hanson J, Deschênes J, Lesniak D, Sabri S. Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. JCO. 2011;29(21):2852-2858. doi:10.1200/jco.2010.33.4714

Wang S, Sun Y, Zhao S, Wei F, Yang G. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients. Mathematical Biosciences and Engineering. 2020;17(1):92-104. doi:10.3934/mbe.2020005

Steward LT, Gao F, Taylor MA, Margenthaler JA. Impact of radiation therapy on survival in patients with triple-negative breast cancer. Oncology Letters. 2013;7(2):548-552. doi:10.3892/ol.2013.1700

To NH, Nguyen HQ, Thiolat A, et al. Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review. Breast Cancer Res Treat. 2022;193(2):265-279. doi:10.1007/s10549-022-06533-3

Isakoff SJ. Triple-Negative Breast Cancer. The Cancer Journal. 2010;16(1):53-61. doi:10.1097/ppo.0b013e3181d24ff7

Xu Y, Diao L, Chen Y, et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. Annals of Oncology. 2013;24(6):1498-1505. doi:10.1093/annonc/mdt011

Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology. 2008;26(8):1275-1281. doi:10.1200/jco.2007.14.4147

Wu J, Li S, Jia W, Su F. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137(10):1505-1510. doi:10.1007/s00432-011-1029-6

Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019;19(1). doi:10.1186/s12885-019-6253-5

Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research. 2016;22(15):3764-3773. doi:10.1158/1078-0432.ccr-15-2477

Mayer IA, Zhao F, Arteaga CL, et al. Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. JCO. 2021;39(23):2539-2551. doi:10.1200/jco.21.00976

Saleh RR, Nadler MB, Desnoyers A, Meti N, Fazelzad R, Amir E. Platinum-based chemotherapy in early-stage triple negative breast cancer: A meta-analysis. Cancer Treatment Reviews. 2021;100:102283. doi:10.1016/j.ctrv.2021.102283

Li Y, Zhou Y, Mao F, et al. Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis. Breast Cancer Res Treat. 2019;179(3):533-542. doi:10.1007/s10549-019-05513-4

Huo X, Li J, Zhao F, et al. The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis. BMC Cancer. 2021;21(1). doi:10.1186/s12885-021-07791-y

Zhang Z, Ma K, Li J, et al. The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis. Front Pharmacol. 2021;12. doi:10.3389/fphar.2021.771839

Komatsu M, Yoshimaru T, Matsuo T, et al. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. International Journal of Oncology. 2012;42(2):478-506. doi:10.3892/ijo.2012.1744

Wang Q, Xu M, Sun Y, et al. Gene Expression Profiling for Diagnosis of Triple-Negative Breast Cancer: A Multicenter, Retrospective Cohort Study. Front Oncol. 2019;9. doi:10.3389/fonc.2019.00354

Won K, Spruck C. Triple‑negative breast cancer therapy: Current and future perspectives (Review). Int J Oncol. 2020;57(6):1245-1261. doi:10.3892/ijo.2020.5135

Singh DD, Parveen A, Yadav DK. Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance. Biomedicines. 2021;9(11):1512. doi:10.3390/biomedicines9111512

Greenup R, Buchanan A, Lorizio W, et al. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Ann Surg Oncol. 2013;20(10):3254-3258. doi:10.1245/s10434-013-3205-1

Zhu X, Chen L, Huang B, et al. Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer. J Exp Clin Cancer Res. 2021;40(1). doi:10.1186/s13046-021-01930-w

Li C, Hao M, Fang Z, et al. PARP inhibitor plus chemotherapy versus chemotherapy alone in patients with triple-negative breast cancer: a systematic review and meta-analysis based on randomized controlled trials. Cancer Chemother Pharmacol. Published online February 2, 2023. doi:10.1007/s00280-023-04506-x

Chen Z, Wang X, Li X, Zhou Y, Chen K. Deep exploration of PARP inhibitors in breast cancer: Monotherapy and combination therapy. Journal of International Medical Research. 2021;49(2):030006052199101. doi:10.1177/0300060521991019

Simmons AD, Nguyen M, Pintus E. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report. BMC Cancer. 2020;20(1). doi:10.1186/s12885-020-6657-2

Collot T, Niogret J, Carnet M, et al. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports. Mol Med Rep. 2020;23(1). doi:10.3892/mmr.2020.11713

Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecologic Oncology. 2017;147(3):695-704. doi:10.1016/j.ygyno.2017.10.003

Sakach E, Sacks R, Kalinsky K. Trop-2 as a Therapeutic Target in Breast Cancer. Cancers. 2022;14(23):5936. doi:10.3390/cancers14235936

Izci H, Punie K, Waumans L, et al. Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC. JCO. 2021;39(15_suppl):e12558-e12558. doi:10.1200/jco.2021.39.15_suppl.e12558

Bardia A, Mayer IA, Diamond JR, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. JCO. 2017;35(19):2141-2148. doi:10.1200/jco.2016.70.8297

Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529-1541. doi:10.1056/nejmoa2028485

Bardia A, Spring LM, Juric D, et al. 358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer. Annals of Oncology. 2020;31:S394. doi:10.1016/j.annonc.2020.08.460

Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Annals of Oncology. 2009;20(10):1639-1646. doi:10.1093/annonc/mdp062

Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A. Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer. Translational Oncology. 2016;9(5):453-457. doi:10.1016/j.tranon.2016.07.002

Liu JF, Tolaney SM, Birrer M, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. European Journal of Cancer. 2013;49(14):2972-2978. doi:10.1016/j.ejca.2013.05.020

Mery B, Rowinski E, Vallard A, et al. Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study. Oncology. 2019;97(1):1-6. doi:10.1159/000499583

Park HS, Jang MH, Kim EJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern Pathology. 2014;27(9):1212-1222. doi:10.1038/modpathol.2013.251

Si Y, Xu Y, Guan J, et al. Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy. Eng Life Sci. 2020;21(1-2):37-44. doi:10.1002/elsc.202000027

Abdelmalek CM, Hu Z, Kronenberger T, et al. Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer. J Med Chem. 2022;65(6):4616-4632. doi:10.1021/acs.jmedchem.1c01646

Guerrab AE, Bamdad M, Kwiatkowski F, Bignon YJ, Penault-Llorca F, Aubel C. Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer. Oncotarget. 2016;7(45):73618-73637. doi:10.18632/oncotarget.12037

Echavarria I, López-Tarruella S, Picornell A, et al. Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann’s Refined Classification. Clinical Cancer Research. 2018;24(8):1845-1852. doi:10.1158/1078-0432.ccr-17-1912

Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treatment Reviews. 2018;68:102-110. doi:10.1016/j.ctrv.2018.06.005

Gucalp A, Traina TA. Triple-Negative Breast Cancer. The Cancer Journal. 2010;16(1):62-65. doi:10.1097/ppo.0b013e3181ce4ae1

Barton VN, D’Amato NC, Gordon MA, Christenson JL, Elias A, Richer JK. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. HORM CANC. 2015;6(5-6):206-213. doi:10.1007/s12672-015-0232-3

Rice MA, Malhotra SV, Stoyanova T. Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. Front Oncol. 2019;9. doi:10.3389/fonc.2019.00801

Rhanine Y, Bonnefoi HR, Goncalves A, et al. Real-life data of antiandrogens (AA) use in metastatic androgen receptor positive triple negative breast cancer (AR+ TNBC): The ATOVAT retrospective French cohort. JCO. 2022;40(16_suppl):e13074-e13074. doi:10.1200/jco.2022.40.16_suppl.e13074

Sharifi M, Wisinski K, Burkard M, et al. Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer. Cancer Research. 2019;79(4_Supplement):OT1-02-01-OT1-02-01. doi:10.1158/1538-7445.sabcs18-ot1-02-01

Kong Y, Qu F, Yuan X, Yan X, Yu W. Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells. Medicine. 2020;99(17):e19822. doi:10.1097/md.0000000000019822

Khan MA, Jain VK, Rizwanullah Md, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today. 2019;24(11):2181-2191. doi:10.1016/j.drudis.2019.09.001

​​Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR. Pharmacological Profiling of Kinase Dependency in Cell Lines across Triple-Negative Breast Cancer Subtypes. Molecular Cancer Therapeutics. 2015;14(1):298-306. doi:10.1158/1535-7163.mct-14-0529

Shen Y, Zhu Q, Xiao M, et al. Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop. Cell Death Dis. 2022;13(8). doi:10.1038/s41419-022-05185-x

Wan X, Zheng X, Pang X, et al. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. International Journal of Pharmaceutics. 2015;484(1-2):16-28. doi:10.1016/j.ijpharm.2015.02.037

Kasikara C, Davra V, Calianese D, et al. Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti–PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer. Cancer Research. 2019;79(10):2669-2683. doi:10.1158/0008-5472.can-18-2614